Please try another search
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
Name | Age | Since | Title |
---|---|---|---|
Jeremy Max Levin | 70 | 2014 | President, CEO & Chairman |
Amit Rakhit | 54 | 2019 | Member of Scientific & Clinical Advisory Board |
Barbara G. Duncan | 59 | 2017 | Independent Director |
Karen Bernstein | 71 | 2015 | Independent Director |
Bart Friedman | 79 | 2015 | Lead Independent Director |
Kevin Joseph Fitzgerald | 55 | 2021 | Independent Director |
Robert Michael Poole | 66 | 2021 | Independent Director |
Jacqueline A. French | - | 2017 | Member of Scientific & Clinical Advisory Board |
Alexander Kolevzon | - | 2020 | Member of Scientific & Clinical Advisory Board |
Joy A. Cavagnaro | - | 2021 | Member of the Scientific & Clinical Advisory Board |
Robert S. Langer | 75 | 2021 | Chairman of the Scientific & Clinical Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review